U.S. Markets close in 6 hrs 21 mins

RegeneRx Biopharmaceuticals, Inc. (RGRX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.29+0.01 (+4.98%)
As of 3:46PM EDT. Market open.
People also watch

RegeneRx Biopharmaceuticals, Inc.

15245 Shady Grove Road
Suite 470
Rockville, MD 20850
United States

IndustryDrug Manufacturers - Other
Full Time Employees3

Key Executives

Dr. Allan L. Goldstein Ph.D.Founder, Chairman, Chief Scientific Officer and Chairman of Scientific Advisory BoardN/AN/A79
Mr. J. J. FinkelsteinChief Exec. Officer, Pres and Director153.36kN/A65
Mr. Dane R. SaglioChief Financial OfficerN/AN/A59
Mr. Alan Klein MBAChief Bus. OfficerN/AN/AN/A
Mr. Richard J. HindinSec.N/AN/A74
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It also evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.

Corporate Governance

RegeneRx Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.